Most Read Articles
Pearl Toh, Yesterday
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 4 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

Modified Kane formula trumps other IOL power formulas for keratoconus

02 Aug 2020
The cornea, the transparent outermost layer of the eye, protects the eye from infection and physical injury.

The most accurate intraocular lens (IOL) power formula for patients with keratoconus is the modified Kane formula, while the SRK/T outdoes other traditional IOL power formulas, according to the results of a recent study.

In addition, all normal IOL formulas have resulted in hyperopic refractive outcomes that worsened as the corneal power increased.

This retrospective consecutive case series analysed data from 14 eyes of 147 patients with keratoconus who had preoperative IOLMaster biometry. A single eye for each eligible patient was randomly selected.

The authors then calculated the predicted refraction for each of the formulas (modified IOL power formulas: Holladay 2 with keratoconus adjustment and Kane keratoconus formula; traditional IOL power formulas: Barrett Universal 2, Haigis, Hoffer Q, Holladay 1, Holladay 2, Kane, and SRK/T) and compared these with the actual refractive outcome to show the prediction error.

Finally, a subgroup analysis was carried out based on the steepest corneal power measured by biometry (stage 1: ≤48 dioptres [D], stage 2: >48 D and ≤53 D, and stage 3: >53 D).

The following formulas were ranked based on the mean absolute prediction error (MAE): Kane keratoconus formula (0.81 D), SRK/T (1.00 D), Barrett Universal 2 (1.03 D), unmodified Kane (1.05 D), Holladay 1 (1.18 D), unmodified Holladay 2 (1.19 D), Haigis (1.22 D), Hoffer Q (1.30 D), and Holladay 2 with keratoconus adjustment (1.32 D).

The Kane keratoconus formula demonstrated a statistically significant lower MAE compared with all formulas, modified or otherwise (p<0.01). Furthermore, all nonmodified formulas had a hyperopic mean prediction error ranging from 1.72 to 3.02 D in stage 3 keratoconus.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, Yesterday
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 4 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.